Rx-to-OTC switches of asthma drugs
Executive Summary
Will be discussed by FDA's Nonprescription Drugs and Pulmonary-Allergy Drugs Advisory Committees during joint meeting Nov. 14. As part of broader discussion of OTC anti-asthma products, committee will discuss "anti-asthma drug products currently available by prescription only that could be considered for OTC status" and "data requirements necessary to support conversion of prescription anti-asthma drug products to OTC." In July 7 Federal Register notice, FDA announces availability of background document for the committee meeting. The meeting will take place at FDA's Parklawn building, conference rooms G through J, beginning at 8:30 a.m
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth